Abstract
Patients with moderate-to-severe atopic dermatitis may have partial or non-durable responses to subcutaneous dupilumab, the first targeted systemic agent approved for this indication. Subsequent management approaches in such patients include optimising topical therapy, considering alternative diagnoses, adjusting the dosage of dupilumab dosage and/or using dupilumab in combination with traditional systemic immunosuppressive agents.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Beck LA, Thaci D, Hamilton JD, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med. 2014;371(2):130–9.
Dupixent (dupilumab) 300 mg solution for injection in prefilled syringe and pen: summary of product characteristics. Paris: Sanofi-Aventis Groupe; 2019.
Dupixent® (dupilumab) injection, for subcutaneous use: US prescribing information. Tarrytown: Regeneron Pharmaceuticals, Inc.; 2019.
Hendricks AJ, Lio PA, Shi VY. Management recommendations for dupilumab partial and non-durable responders in atopic dermatitis. Am J Clin Dermatol. 2019;20(4):565–9.
Simpson EL, Bieber T, Guttman-Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375:2335–48.
Yu SH, Drucker AM, Lebwohl M, et al. A systematic review of the safety and efficacy of systemic corticosteroids in atopic dermatitis. J Am Acad Dermatol. 2018;78(4):733–40.
Thomas LW, Elsensohn A, Bergheim T, et al. Intramuscular steroids in the treatment of dermatologic disease: a systematic review. J Drugs Dermatol. 2018;17(3):323–9.
Margolin L, Cope DK, Bakst-Sisser R, et al. The steroid withdrawal syndrome: a review of the implications, etiology, and treatments. J Dermatol Treat. 2018;29(4):364–74.
Sidbury R, Davis DM, Cohen DE, et al. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol. 2014;71(2):327–49.
Colmenero CG, Morente GB, Sánchez JT. Oral cyclosporine weekend therapy: a new maintenance therapeutic option in patients with severe atopic dermatitis. Pediatr Dermatol. 2015;32(4):551–2.
Dehesa L, Abuchar A, Numo-Gonzalez A, et al. The use of cyclosporine in dermatology. J Drug Dermatol. 2012;11(8):979–87.
Vena GA, Cassano N, Iannone F. Update on subcutaneous methotrexate for inflammatory arthritis and psoriasis. Ther Clin Risk Manag. 2018;18:105–16.
Author information
Authors and Affiliations
Consortia
Contributions
The article was written by employees of Adis International Ltd./Springer Nature and was adapted, in part, from the American Journal of Clinical Dermatology 2019;20(4):565–9 [4].
Ethics declarations
Funding
The preparation of this review was not supported by any external funding.
Conflict of interest
The authors declare no conflicts of interest.
Rights and permissions
About this article
Cite this article
Adis Medical Writers. Modify treatment for atopic dermatitis when patient response to dupilumab is partial or non-durable. Drugs Ther Perspect 36, 186–189 (2020). https://doi.org/10.1007/s40267-020-00715-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40267-020-00715-z